in vivo CAR-T drug based on LNP-mRNA: in vivo CAR-T drug based on LNP-mRNA
Study summary
Malignant hematological tumors mainly derived from adult B cells are mainly acute lymphoblastic leukemia (ALL) and non Hodgkin lymphoma (NHL). Overall, although existing therapies have significantly improved the survival rates of most patients, the treatment of relapsed/refractory patients still faces significant challenges. CD19 is one of the most clinically valuable targets for B-cell malignant hematological tumors.
The advent of COVID-19 vaccine has brought LNP mRNA technology into the public's view. After years of development, it not only shines brilliantly in COVID-19 vaccine, but also is widely used in the treatment and exploration of cancer, rare diseases and other fields. Lipid nanoparticles (LNP) are currently the most mature non viral delivery platform, capable of protecting mRNA from nuclease degradation, promoting intracellular uptake, and achieving efficient translation in vivo.
The core of LNP-mRNA technology targeting CD19 is to encapsulate the mRNA encoding specific proteins (such as anti-CD19 related proteins) in lipid nanoparticles and deliver them to the body through intravenous or intramuscular injection.
Eligibility
Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
* 1\. Age range of 18-70 years old, gender not limited;
* 2\. Expected survival time exceeds 12 weeks;
* 3\. B-cell lymphoma or lymphocytic leukemia diagnosed with CD19+, with no standard treatment options recommended according to guidelines
* 4\. There are assessable lesions (applicable only to lymphoma patients);
* 5\. The physical fitness status score of the Eastern Cancer Collaboration Group (ECOG) is 0 or 1;
* May involve other inclusion criteria
Exclusion Criteria:
* 1\. Accompanied by other uncontrolled malignant tumors;
* 2\. Previously received chimeric antigen receptor therapy or other transgenic T cell therapy;
* 3\. Known history of HIV or hepatitis B (HBsAg positive and HBV DNA reaching the detection limit) or hepatitis C virus (anti HCV positive) infection;
* 4\. Participants with a history of CNS lymphoma, malignant cells in cerebrospinal fluid, or brain metastases;
* 5\. The researcher believes that there are any other factors that are not suitable for the study participants to enter this trial.
May involve other exclusion criteria
Primary outcome measure(s)
Dose limiting toxicity (DLT) and its incidence rate — Within 28 days after the initial treatment
Maximum tolerated dose (MTD) or optimal biological dose (OBD) — 3 months
Trial sites (1)
Facility
City
Region
Status
Department of Hematology, Xinqiao Hospital
Chongqing
Chongqing Municipality
Recruiting
More Xinqiao Hospital of Chongqing trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.